Background: Allergic responses to common environmental agents are believed to be involved in the development of atopic dermatitis, but clinical usefulness of allergen-specific immunotherapy in the treatment of atopic dermatitis is controversial. We performed a pilot study to evaluate the clinical usefulness of combined treatment with allergen-specific immunotherapy and a histamine-immunoglobulin complex in patients with atopic dermatitis. Methods: Twenty patients with atopic dermatitis and hypersensitivity to house dust mites whose clinical conditions had not been effectively controlled by current standard medical therapies were treated with a combination of allergen-specific immunotherapy using house dust mite extract and a histamine-immunoglobulin complex for 12 months. The primary efficacy outcome was the change in the standardized clinical severity scoring system for atopic dermatitis (SCORAD) values at 6 and 12 months in comparison with the values at baseline. Results: In 18 patients who completed all 12 months of treatment, the SCORAD values significantly decreased from 43.6 ± 15.9 at baseline to 27.8 ± 18.3 at 6 months and 18.3 ± 14.9 at 12 months (Wilcoxon signed-rank test, p < 0.001), and no significant systemic side effects were observed. Conclusions: In this uncontrolled pilot study, combined treatment with allergen-specific immunotherapy and a histamine-immunoglobulin complex resulted in significant clinical improvements in patients with atopic dermatitis. However, double-blind placebo-controlled studies are necessary to test the clinical usefulness of this modified allergen-specific immunotherapy for atopic dermatitis.

1.
Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, et al: Guidelines of care for atopic dermatitis. J Am Acad Dermatol 2004;50:391–404.
2.
Ellis C, Luger T, Abeck D, Allen R, Graham-Brown RA, De Prost Y, et al: International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 2003;148:3–10.
3.
Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, et al: Diagnosis and treatments of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006;118:152–169.
4.
Flohr C, Johansson SGO, Wahlgren CF, Williams H: How atopic is atopic dermatitis? J Allergy Clin Immunol 2005;114:150–158.
5.
Novak N, Bieber T, Leung DYM: Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 2003;112:S128–S139.
6.
Platts-Mills TA, Mitchell EB, Rowntree S, Chapman MD, Wilkins SR: The role of dust mite allergens in atopic dermatitis. Clin Exp Dermatol 1983;8:233–247.
7.
Tupker RA, De Monchy JG, Coenraads PJ, Homan A, van der Meer JB: Induction of atopic dermatitis by inhalation of house dust mite. J Allergy Clin Immunol 1996;97:1064–1070.
8.
Tan BB, Weald D, Strickland I, Friedmann PS: Double-blind controlled trial of effect of house dust-mite allergen avoidance on atopic dermatitis. Lancet 1996;347:15–18.
9.
Bousquet J, Lockey R, Malling HJ, WHO panel members: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102:558–562.
10.
Glover MT, Atherton DJ: A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy 1992;22:440–446.
11.
Clinical Research Group for Histaglobin: Double blind controlled study on the efficacy of histaglobin on chronic urticaria and eczematous dermatitis (in Japanese). Nishinipponifuka 1980;42:470–477.
12.
Yoshii H, Fukata-Yamazaki Y, Yamamoto K, Yago H, Yanagihara Y, Okudaira H: A complex of histamine/mouse gamma-globulin preferentially inhibits allergen-induced peritoneal accumulation of eosinophils, but not neutrophils, in mice. J Allergy Clin Immunol 1997;100:809–816.
13.
Gelfand HH, Cinder JC, Grant SF, Soiffer M: Evaluation of histamine-gamma globulin (histaglobin) in the treatment of various allergic conditions. Ann Allergy 1963;21:150–155.
14.
Ayoub M, Lallouette P, Sutterlin BW, Bessler WG, Huber M, Mittenbuhler K: Modulation of the Th1/Th2 bias by an immunoglobulin histamine complex in the ovalbumin allergy mouse model. Int Immunopharmacol 2003;3:523–539.
15.
Hanifin JM, Rajka G: Diagnostic features of atopic eczema. Acta Derm Venereol (Stockh) 1980;92:44–47.
16.
European Task Force on Atopic Dermatitis: Severity scoring of atopic dermatitis: the SCORAD index. Dermatology 1993;186:23–31.
17.
Griffin CE, Hillier A: The ACVD task force on canine atopic dermatitis (XXIV): allergen-specific immunotherapy. Vet Immunol Immunopathol 2001;81:363–383.
18.
Werfel T, Breuer K, Ruéff F, Przybilla B, Worm M, Grewe M, et al: Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-dependent study. Allergy 2006;61:202–205.
19.
Bussmann C, Bockenhoff A, Henke H, Werfel T, Novak N: Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis. J Allergy Clin Immunol 2006;118:1292–1298.
20.
Leory BP, Boden G, Lachapelle JM, Jacquemin MG, Saint-Remy JM: A novel therapy for atopic dermatitis with allergen-antibody complexes: a double-blind, placebo-controlled study. J Am Acad Dermatol 1993;28:232–239.
21.
Hoare C, Li Wan Po A, Williams H: Systematic review of treatments of atopic eczema. Health Technol Assess 2000;4:1–191.
22.
Mueller RS, Veir J, Fieseler KV, Dow SW: Use of immunostimulatory liposome-nucleic acid complexes in allergen-specific immunotherapy of dogs with refractory atopic dermatitis – a pilot study. Vet Dermatol 2005;16:61–68.
23.
Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Washio Y, Ohno Y, et al: Risk factors for adverse systemic reactions occurring during immunotherapy with standardized Dermatophagoides farinae extracts. Acta Otolaryngol Suppl 1998;538:113–117.
24.
Ohashi Y, Nakai Y, Kiyotaka M: Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2006;4:600–605.
25.
Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ: Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006;54:68–72.
26.
Krathen RA, Hsu S: Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005;53:338–340.
27.
Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, Deniz Y: Pharmacodynamics of omalizumab: implications for optimized dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003;19:491–498.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.